Research Article | OPEN ACCESS
Antimalarial Drug Resistance: In the Past, Current Status and Future Perspectives
Mebrahtu Eyasu
Saint Paul’s Hospital Millennium Medical College, Department of Pharmacology, P.O. BOX 1271, Addis Ababa, Ethiopia, Tel.: 0913-51-80-25
British Journal of Pharmacology and Toxicology 2015 1:1-15
Received: August ‎22, ‎2014 | Accepted: September ‎20, ‎2014 | Published: February 20, 2015
Abstract
The aim of this study was to review the antimalarial drug treatment and its resistance during the course of therapy. Malaria affects the populations of tropical and subtropical areas world-wide, as well as an increasing number of travellers to these areas. Although malaria is found in over 100 countries, the major burden of disease is carried by the nations of Africa, where over 90% of all deaths from falciparum malaria are recorded and where the high levels of morbidity and transmission place considerable strains on public health services and economic infrastructure. In the absence of effective vaccines, management of the disease has depended largely upon chemotherapy and chemoprophylaxis. The number of available and effective antimalarial drugs is quickly dwindling due to different cause. This is mainly because a number of drug resistance-associated mutations in malaria parasite genes, such as crt, mdr1, dhfr/dhps and others, have led to widespread resistance to all known classes of antimalarial compounds. Unfortunately, malaria parasites have started to exhibit some level of resistance in Southeast Asia even to the most recently introduced class of drugs, artemisinins. Molecular evolutionary and population genetic approaches will greatly facilitate our understanding of the evolution and spread of parasite drug resistance and will contribute to developing strategies for better control of malaria. While there is much need, the antimalarial drug development pipeline remains woefully thin, with little chemical diversity and there is currently no alternative to the precious artemisinins. In general, four basic methods have been routinely used to study or measure antimalarial drug resistance: in vivo, in vitro, animal model studies and molecular characterization. This review endeavors to present the background facts and treatment and more on the current status of antimalarial drug resistance, what their causes, mechanisms, spread and management are and future perspective with antimalarial treatment. Furthermore, findings from this review will be useful to clinical researchers, health planners, policy makers and stakeholders and others concerned for malaria patients.
Keywords:
Detection of resistance, drug resistance, malaria, mutation, p. falciparum, p.vivax,
References
- Anvikar, A.R., B. Sharma, S.K. Sharma, S.K. Ghosh, R.M. Bhat, A. Kumar, S.S. Mohanty and C.R. Pillai, 2012. In vitro assessment of drug resistance in Plasmodium falciparum in five States of India. Indian J. Med. Res., 135: 494-499.
PMid:22664496 PMCid:PMC3385232
- Aminake, M.N. and G. Pradel, 2013. Antimalarial drugs resistance in Plasmodium falciparum and the current strategies to overcome them. Microbial pathogens and strategies for combating them: science, technology and education (A. Méndez-Vilas, Ed.). © FORMATEX 2013.
- Alene, G.D. and S. Bennett, 1996. Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea. Trop. Med. Int. Health, 1: 810-815.
CrossRef PMid:8980594
- Austin, D.J. and R.M. Anderson, 1999. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos. Trans. R. Soc. Lond. B Biol. Sci., 354: 721-738.
CrossRef PMid:10365398 PMCid:PMC1692559
- Adugna, A., 2009. Malaria in Ethiopia. Retrieved form: http:// www. ethiodemo graphyandhealth. org. (Accessed on: July 2, 2014).
Direct Link
-
Briolant, S., H. Bogreau, M. Gil, H. Bouchiba, E. Baret, R. Amalvict, C. Rogier and B. Pradines, 2012. The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates. Antimicrob. Agents Chemother., 56: 2750-2752.
CrossRef PMid:22314533 PMCid:PMC3346656
-
Batista, R., J.S. Junior and A.B. Oliveira, 2009. Plant derived antimalarial agents. Molecules, 14: 3037-3072.
CrossRef PMid:19701144
- Beith, A., 2008. Mapping Factors that Drive Drug Resistance (with a Focus on Resource-Limited Settings): A First Step towards Better Informed Policy. Retrieved form: www. cgdev. org/ drug_resistance. (Accessed on: August 2, 2014).
Direct Link
-
Bauchner, H., S.I. Pelton and J.O. Klein, 1999. Parents, physicians and antibiotic use. Pediatrics., 103: 395-401.
CrossRef PMid:9925831
- Basco, L.K., 2007. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Switzerland, Geneva.
PMCid:PMC2732998
-
Bosman, A., C. Delacollette, P. Olumese, R.G. Ridley, A. Rietveld, R. Shretta and A. Teklehaimanot, 2001. The use of antimalarial drugs: Report of an Informal Consultation. Roll Back Malaria World Health Organization, Switzerland, 8.
- Borrmann, S. and K. Matuschews, 2011. Targeting plasmodium liver stages: Better late than never. Trends Molecular Med., x: 1-10.
CrossRef
-
Charles, O.O., R.T. Walter, O. Bernhards, V. John and E.G. Diederick, 2000. Prevalence of and risk factors for malaria-associated anaemia in young Kenyan children. 5.
-
Costanzo, M.S. and D.L. Hartl, 2011. The evolutionary landscape of antifolate resistance in Plasmodium falciparum. J. Genet., 90: 187-190.
CrossRef PMid:21869466 PMCid:PMC3212943
-
Cui, L. and X.Z. Su, 2009. Discovery, mechanisms of action and combination therapy of artemisinin. Exp. Rev. Anti-Infective Therap., 7(8): 999-1013.
CrossRef PMid:19803708 PMCid:PMC2778258
- CDC (Centers for Disease Control and Prevention), 2014. Global Health Strategy, 2012-2015.
- Dondorp, A.M., F. Nosten, P. Yi, D. Das and A.P. Phyo, 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med., 361: 455-467.
CrossRef PMid:19641202 PMCid:PMC3495232
- Daily, J.P., 2006. Antimalarial drug therapy: The role of parasite biology and drug resistance. J. Clin. Pharma., 46(12): 1487-1497.
CrossRef PMid:17101748
- Ding, X.C., H.P. Beck and G. Raso, 2011. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol., 27(2): 73-81.
CrossRef PMid:21169061
- Eyasu, M., W. Shibeshi and M. Giday, 2013. In vivo antimalarial activity of hydromethanolic leaf extract of Calpurnia aurea (Fabaceae) in Mice infected with chloroquine sensitive Plasmodium berghei. Int. J. Pharm. Pharmacol., 2(9): 131-142.
-
Foote, S.J., D. Galatis and A.F. Cowman, 1990. Amino acids in the dihydrofolate reductasethymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA, 87: 3014-3017.
CrossRef PMid:2183221 PMCid:PMC53824
- Fisher, N., R.A. Majid and T. Antoine, 2012. Cytochrome b mutation Y268S conferring the atovaquone resistance phenotype in the malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. The American Society for Biochemistry and Molecular Biology, Inc., Retrieved form: http://www.jbc.org/cgi/doi/ 10.1074/jbc.M111.324319. (Accessed on: June 12, 2014).
Direct Link
-
Fairhurst, R.M., G.M. Nayyar, J.G. Breman, R. Hallett, J.L. Vennerstrom, S. Duong and P. Ringwald, 2012. Artemisinin-resistant malaria: Research challenges, opportunities and public health implications. Am. J. Trop. Med. Hyg., 87: 231-224.
CrossRef PMid:22855752 PMCid:PMC3414557
-
Foley, M. and L. Tilley, 1997. Quinoline antimalarials: Mechanisms of action and resistance. Int. J. Parasitol., 27: 231-240.
CrossRef
-
Golenda, C.F., J. Li and R. Rosenberg, 1997. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proceedings of the National Academy of Sciences of the United States of America, 94: 6786-6791.
CrossRef PMid:9192643 PMCid:PMC21236
- Gardiner, D.L., T.S. Skinner-Adams, C.L. Brown, K.T. Andrews, C.M. Stack, J.S. McCarthy, J.P. Dalton and K.R. Trenholme, 2009. Plasmodium falciparum: New molecular targets with potential for antimalarial drug development. Expert Rev. Anti Infect. Ther., 7(9): 1087-1098.
CrossRef PMid:19883329
- Gregson, A. and C. Plowe, 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev., 57: 117-145.
CrossRef PMid:15734729
- Grimberg, B.T. and R.K. Mehlotra 2011. Review on Expanding the Antimalarial Drug Arsenal-Now, But How? Retrieved form: www.mdpi.com/ journal/pharmaceuticals. (Accessed on: July 4, 2014).
Direct Link
- Hastings, I.M. and W.M. Watkins, 2006. Tolerance is the key to understanding antimalarial drug resistance. TRENDS in Parasitol., 22(2): 2-3.
CrossRef PMid:16406706
- Hyde, J.E., 2007. Drug-resistant malaria-An insight. FEBS J., 274: 4688-4698.
CrossRef PMid:17824955 PMCid:PMC2720519
-
Hyde, J.E., 2002. Current focus Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infection, 4: 165-174.
CrossRef
- Imwong, M., A.M. Dondorp, F. Nosten, P. Yi, M. Mungthin, S. Hanchana, D. Das and et al., 2010. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother., 54: 2886-2892.
CrossRef PMid:20421395 PMCid:PMC2897287
- Jain, P., B. Chakma, S. Patra and P. Goswami, 2014. Potential biomarkers and their applications for rapid and reliable detection of malaria. BioMed Res. Int., Retrieved form: http://dx.doi.org/10. 1155/2014/852645.
Direct Link
- Jones, M.K., Good, M.F., 2006. Life cycle of malaria in humans. Nature Medicine, 12: 170 - 171.
CrossRef PMid:16462797
-
Khattak, A.A., M. Venkatesan, L. Khatoon, A. Ouattara, L.J. Kenefic and M.F. Nadeem, 2013. Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan. Malaria J., 12: 310.
CrossRef PMid:24007534 PMCid:PMC3766695
- Klein, E.Y., 2012. Antimalarial Drug Resistance. A Dissertation Presented to the Faculty of Princeton University in Candidacy for the Degree of Doctor of Philosophy. Princeton University.
-
Klein, E.Y., 2013. Antimalarial drug resistance: A review of the biology and strategies to delay emergence and spread. Int. J. Antimicrob. Agents, 41: 311-317.
CrossRef PMid:23394809 PMCid:PMC3610176
-
Krogstad, D.J., 1987. Efflux of chloroquine from Plasmodium falciparum: Mechanism of chloroquine resistance. Science, 238: 1283-1285.
CrossRef PMid:3317830
- Lau, Y.L., M.Y. Fong, R. Mahmud, P.Y. Chang, V. Palaeya, F.W. Cheong and L.C. Chin, 2011. Specific, sensitive and rapid detection of human plasmodium knowlesi infection by loop-mediated isothermal amplification (LAMP) in blood samples. Malaria J., 10: 197.
CrossRef PMid:21774805 PMCid:PMC3156799
- Luzzatto, L., 2010. The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics. Lancet, 376: 739-741.
CrossRef
- Lackritz, E., 1991. Imported Plasmodium falciparum malaria in American travelers to Africa. Implications for prevention strategies. J. Amer. Med. Association, 265: 383-385.
CrossRef PMid:1984539
-
Laufer, M.K., 2009. Monitoring antimalarial drug efficacy: Current challenges. Curr. Infect. Dis. Rep., 11(1): 59-65.
CrossRef PMid:19094826 PMCid:PMC2695491
- Lee, P.W., D.D. Ji, C.T. Liu and H.S. Rampao, 2012. Application of loop-mediated isothermal amplification for malaria diagnosis during a follow up study in Sao Tome. Malaria J., 11: 408.
CrossRef PMid:23217163 PMCid:PMC3528453
-
Lu, F., B. Wang, J. Cao and J. Sattabongkot, 2012. Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in central China. Korean J. Parasitol., 50(4): 379-384.
CrossRef PMid:23230341 PMCid:PMC3514435
-
Lamar, J., R. Martschinske, G. Tetreault and C. Doud, 2007. Navy Medical Department pocket guide to malaria prevention and control. pp: 1-112.
- Lee, S.J., E. Seo and Y. Cho, 2013. Proposal for a new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference. Int. J. Parasitol. Drugs Drug Resistance, 3: 119-128.
CrossRef PMid:24533301 PMCid:PMC3862410
- Murray, C.J.L., L.C. Rosenfeld, S.S. Lim, K.G. Andrews, K.J. Foreman and D. Haring, 2012. Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet, 379(9814): 413-431.
CrossRef
- Mathers, C.D., A.D. Lopez and C.J.L. Murray, 2006. The Burden of Disease and Mortality by Condition: Data, Methods and Results for 2001. Global Burden of Disease and Risk Factors. The International Bank for Reconstruction and Development/ The World Bank, pp: 45-240.
-
Morassin, B., R. Fabre, A. Berry and J.F. Magnaval, 2002. One year's experience with the polymerase chain reaction as a routine method for the diagnosis of imported malaria. Amer. J. Trop. Med. Hygiene, 66(5): 503-508.
CrossRef PMid:12201583
- Martin, S.K., A.M. Oduola and W.K. Milhous, 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science, 235: 899-901.
CrossRef PMid:3544220
- Mahajan, R.C. and F. Umar, 2004. Drug resistance in malaria. J. Vect. Borne Dis., 41: 5.
- Mehlotra, R.K. and P.A. Zimmerman, 2006. Resistance to Antimalarial Drugs: Parasite and Host Genetic Factors. In: Dronamraju, K.R. and P. Arese, (Eds.), Malaria: Genetic and evolutionary aspects. Springer, New York, NY.
CrossRef
- Mideo, N., D.A. Kennedy, J.M. Carlton, J.A. Bailey, J.J. Juliano and A.F. Read, 2013. Ahead of the curve: Next generation estimators of drug resistance in malaria infections. Trends Parasitol., 29(7): 321-328.
CrossRef PMid:23746748 PMCid:PMC3694767
- Malaria Consortium, 2014. Disease Control and Better Health. United Kingdom, Retrieved form: info@ malariacon sortium. org/ www. malariaconsortium. org. (Accessed on: August 1, 2014).
Direct Link
- Mubjer, R.A., A.A. Adeel, M.L. Chance and A.A. Hassan, 2011. Molecular markers of antimalarial drug resistance in Lahj Governorate, Yemen: Baseline data and Implications. Malaria J., 10: 245.
CrossRef PMid:21854642 PMCid:PMC3177815
- Meshnick, S.R., T.E. Taylor and S. Kamchonwongpaisan, 1996. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy. Microbiol. Rev., 60: 301-315.
PMid:8801435 PMCid:PMC239445
- Nzila, A., 2006. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemotherap., 57(6): 1043-1054.
CrossRef PMid:16617066
- Noedl, H., C. Wongsrichanalai and W.H. Wernsdorfer, 2003. Malaria drug-sensitivity testing: New assays, new perspectives. TRENDS Parasitol., 19: 4.
CrossRef
-
Nwaka, S. and A. Hudson, 2006. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug. Discov., 5: 941-955.
CrossRef PMid:17080030
- Olliaro, P., 2001. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Therapeutics, 89: 207-219.
CrossRef
- Olliaro, P. and T.N. Wells, 2009. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther., 85: 584-595.
CrossRef PMid:19404247
- Pillay, P., 2006. Malaria and Antimalarials from Plants. University of Pretoria Edn., South Africa, pp: 1-20.
-
Paul, E.W., A.P. Alisa and R.M. Steven, 2005. Real-time PCR methods for monitoring antimalarial drug resistance. Trends Parasitol., 21: 278-283.
CrossRef PMid:15922249
- Petersen, I., R. Eastman and M. Lanzer, 2011. Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Letters, 585: 1551-1562.
CrossRef PMid:21530510
- Plowe, C.V., 2003. Monitoring antimalarial drug resistance: Making the most of the tools at hand. J. Experimental Biol., 206: 3745-3752.
CrossRef PMid:14506209
- Price, R.N., 1996. Effects of artemisinin derivatives on malaria transmissiblity. Lancet, 347: 1654-1658.
CrossRef
- Price, R.N., E. Tjitra, C.A. Guerra, S. Yeung, N.J. White and N.M. Anstey, 2007. Vivax malaria: Neglected and not benign. Am. J. Trop. Med. Hyg., 77: 79-87.
PMid:18165478 PMCid:PMC2653940
- Peter, A., A. Winstanley, A. Steven, B. Ward, W. Robert and C.D. Snow, 2002. Current focus Clinical status and implications of antimalarial drug resistance. Microbes Infection, 4: 157-164.
CrossRef
- Robert, V., A.H. Awono, J. Hesran and J. Trape, 2001. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated P. falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. A. J. Trop. Med. Hyg., 62: 210-216.
CrossRef
-
Ringwald, P. and L.K. Basco, 1999. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquinein Yaoundé, Cameroon. Bull. World Health Organiz., 77(1).
- Snow, R.W., C.A. Guerra, A.M. Noor, H.Y. Myint and S.I. Hay, 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 434(7030): 214-217.
CrossRef PMid:15759000 PMCid:PMC3128492
- Shillcutt, S., C. Morel, C. Goodman, P. Coleman, D. Bell, C.J.M. Whitty and A. Mills, 2008. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull.World Health Organiz., 86(2): 101-110.
CrossRef PMid:18297164 PMCid:PMC2647374
-
Saifi, M.A., T. Beg, A.H. Harrath, F.S. Altayala and S.A. Quraishy, 2012. Antimalarial drugs: Mode of action and status of resistance. Afr. J. Pharm. Pharmacol., 7(5): 148-156.
CrossRef
-
Sidhu, A.B., D. Verdier-Pinard and D.A. Fidock, 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science, 298: 210-213.
CrossRef PMid:12364805 PMCid:PMC2954758
- Shretta, R., J. Omumbo, B. Rapouda and R.W. Snow, 2000. Using evidence to change anti-malarial drug policy in Kenya. Trop. Med. Int. Health, 5: 755-787.
CrossRef PMid:11123822
- Schlitzer, M., 2008. Antimalarial drugs-what is in use and what is in the pipeline. Arch. Pharm. (Weinheim), 341:149-163.
CrossRef PMid:18297679
- Sharma, Y.D., 2012. Molecular surveillance of drug-resistant malaria in India. Current Sci., 102: 5.
-
Shanks, G.D., 2006. Treatment of falciparum malaria in the age of drug-resistance. J. Postgrad. Med., 52: 277-280.
PMid:17102546
- Talisuna, A.O., C. Karema, B. Ogutu, E. Juma, J. Logedi, A. Nyandigisi, M. Mulenga and et al., 2012. Mitigating the threat of artemisinin resistance in Africa: Improvement of drug-resistance surveillance and response systems. Lancet Infect. Dis., 12: 888-896.
CrossRef
- Thera, M.A. and C.V. Plowe, 2012. Vaccines for Malaria: How Close Are We? Annu. Rev. Med., 63: 345-357.
CrossRef PMid:22077719 PMCid:PMC3338248
- Trape, J.F., G. Pison, M.P. Preziosi, C. Enel, L.A. Desgrees and et al., 1998. Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. III, 321: 689-697.
CrossRef
- Teuscher, F., M.L. Gatton, N. Chen, J. Peters, D.E. Kyle and Q. Cheng, 2010. Artemisinin-induced dormancy in Plasmodium falciparum: Duration, recovery rates and implications in treatment failure. J. Infect. Dis., 202: 1362-1368.
CrossRef PMid:20863228 PMCid:PMC2949454
- Talisuna, A.O., P.D. Bloland and U. Alessandro, 2004. History, dynamics and public health importance of malaria parasite resistant. Clin. Microbiol. Rev., 17: 235-254.
CrossRef PMid:14726463 PMCid:PMC321461
- Van, T.D., J.P. Daniel, F.S. Stephen, E.N. Daniel and et al., 2011. Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genetics, 7(4): e1001383.
CrossRef PMid:21533027 PMCid:PMC3080868
-
Valderramos, S.G. and D.A. Fidock, 2006. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci., 27: 594-601.
CrossRef PMid:16996622 PMCid:PMC2944664
-
Vernet, G., C. Mary, D.M. Altmann, O. Doumbo, S. Morpeth, Z.A. Bhutta and K.P. Klugman, 2014. Surveillance for antimicrobial drug resistance in under-resourced countries. Emerg. Infectious Dis., 20: 3.
CrossRef PMid:24564906 PMCid:PMC3944851
-
Wang, X., J. Mu, G. Li, P. Chen, X. Guo, L. Fu, L. Chen, X. Su and T.E. Wellems, 2005. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am. J. Trop. Med. Hyg., 72: 410-414.
PMid:15827277
-
Ward, S.A. and I.C. Boulton, 2013. CRIMALDDI: A prioritized research agenda to expedite the discovery of new anti-malarial drugs. Malaria J., 12: 395.
CrossRef PMid:24191947 PMCid:PMC3830512
- Wernsdorfer, W.H. and D. Payne, 1991. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol. Ther., 50: 95-121.
CrossRef
- Wernsdorfer, W.H., T. Chongsuphajaisiddhi and N.P. Salazar, 1994. A symposium on containment of mefloquine resistant falciparum malaria in Southeast Asia with special reference to border malaria. Southeast Asian J. Trop. Med. Pub. Health, 25: 11-18.
PMid:7825000
-
White, N.J., 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial Agents Chemotherap., 41: 413-1422.
- White, N.J., 1999. Averting a malaria disaster. Lancet, 353: 1965-1967.
CrossRef
- White, N.J., 2004. Antimalarial drug resistance. J. Clin. Invest., 113: 1084-1092.
CrossRef PMid:15085184 PMCid:PMC385418
- White, N.J., 2008. Qinghaosu (artemisinin): The price of success. Science, 320: 330-334.
CrossRef PMid:18420924
- WHO, 1967. Chemotherapy of malaria. Report of a WHO Scientific Group. Geneva, Switzerland.
- WHO, 1973. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO Scientific Group. WHO Technical Report Series, No. 529. Switzerland, Geneva.
- WHO, 1993. Implementation of the Global Malaria Control Strategy: Report of a WHO Study Group on the implementation of the global plan of action for malaria control 1993-2000. Technical Report Series No. 839.
- WHO, 2001. Department of Communicable Disease Surveillance and Response. Drug resistance in malaria. Retrieved form: http://www.who.int/emc. (Accessed on: May 23/2014).
Direct Link
- WHO, 2009. Strategy Paper on Management of Antimalarial Drug Resistance for the Roll Back Malaria (RBM) Board. Retrieved form: http:// apps.who.int/malaria/docs/drugresistance/ Protocol). (Accessed on: July 7, 2014).
- WHO, 2010. Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010.
- WHO, 2011. Global Plan for Artemisinin Resistance Containment. Retrieved form: www.who.int/ malaria/.../atoz/. (Accessed on: June 12, 2014).
- WHO, 2012. World Malaria Report. Geneva, Switzerland.
- WHO, 2013a. Global Report on antimalarial drug efficacy and drug resistance: 2000-2010.
-
WHO, 2013b. Antimalarial drug resistance. The World Health Organization, Last Update: 2013. Geneva, Switzerland.
- WHO, 2014. Status Report on Artemisinin Resistance. January, 2014. (July 18, 2014).
- WHO, 2013c. Emergency response to artemisinin resistance in the Greater Mekong Sub region.
-
Wells, T.N.C., P.L., Alonso and W.E. Gutteridge, 2009. New medicines to improve control and contribute to the eradication of malaria. Nature Rev. Drug Discovery, 8: 879.
CrossRef PMid:19834482
- Yusuf, R.U., S.A. Omar and R.M. Ngure, 2010. The effect of Point Mutations in Dihydrofolate reductase genes and the Multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan. J. Infect. Dev. Ctries., 4(2): 61-69.
CrossRef PMid:20212335
Competing interests
The authors have no competing interests.
Open Access Policy
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Copyright
The authors have no competing interests.
|
|
![](http://www.maxwellsci.com/images/BJPT-maxw.jpg) |
ISSN (Online): 2044-2467
ISSN (Print): 2044-2459 |
![Submit Manuscript](../images/sub.jpg) |
Information |
|
|
|
Sales & Services |
|
|
|